Platelet factor III effectiveness test

Platelet factor 3 (PF3) is a phospholipid component of the platelet membrane that provides phospholipid-activated surfaces for factors IXa, VIIIa, and Ca2+ as well as factors Xa, Va, and Ca2+. The method for determining the involvement of platelets in the coagulation process is called platelet factor 3 effectiveness determination (PF3aT). PF3aT reduces congenital and acquired platelet factor 3 deficiency, and is found in cirrhosis, uremia, myeloproliferative syndrome, abnormal proteinemia, disseminated intravascular coagulation (DIC), thrombocytopenia, and drugs. PF3aT is also reduced in patients with platelet weakness. Basic Information Specialist classification: cardiovascular examination classification: blood examination Applicable gender: whether men and women apply fasting: fasting Tips: Try to reduce the amount of exercise before blood draw, do not eat food, keep fasting, you can drink a small amount of water, in addition to some drugs that must be taken on time, try to take other drugs to the blood and then take it, so as not to some experiments The result is interference. In the case of an inpatient, the doctor or nurse should draw blood for you when the amount of physical exercise is relatively stable. Normal value The clotting time is 0~5 seconds. Clinical significance PF3aT reduces congenital and acquired platelet factor 3 deficiency, and is found in cirrhosis, uremia, myeloproliferative syndrome, abnormal proteinemia, disseminated intravascular coagulation (DIC), thrombocytopenia, and drugs. PF3aT is also reduced in patients with platelet weakness. Low results may be diseases: predisposition to disseminated intravascular coagulation and cirrhosis (1) The blood should be centrifuged immediately after mixing with the anticoagulant. (2) PRP is adjusted to (200 ~ 250) × 109 / L, PPP is adjusted to (10 ~ 20) × 109 / L is appropriate. (3) Red blood cells cannot be mixed in the platelet suspension (PRP and PPP). (4) When judging the end point of the experiment, it is necessary to strictly control the appearance of fibrin. Inspection process (1) 2.7 ml of blood was collected by a silicon or plastic syringe, and a silicon or plastic test tube containing 0.109 mol/L sodium citrate anticoagulant 0.3 ml was injected and mixed. The patient and the healthy person simultaneously took one blood each. (2) Anticoagulant sodium citrate was centrifuged at 1000 r/min for 10 min, and the supernatant was taken out as PRP; the remaining disturbed coagulation was centrifuged at 3000 r/min for 15 min, and the supernatant was taken out as PPP. (3) Four small test tubes were divided into 4 groups, and each tube was added with 0.1 ml of PRP and PPP. Not suitable for the crowd 1. Patients who have taken contraceptives, thyroid hormones, steroid hormones, etc., may affect the results of the examination and prohibit patients who have recently taken the drug history. 2, special diseases: patients with hematopoietic function to reduce disease, such as leukemia, various anemia, myelodysplastic syndrome, etc., unless the examination is essential, try to draw less blood. Adverse reactions and risks 1, subcutaneous hemorrhage: due to pressing time less than 5 minutes or blood draw technology is not enough, etc. can cause subcutaneous bleeding. 2, discomfort: the puncture site may appear pain, swelling, tenderness, subcutaneous ecchymosis visible to the naked eye. 3, dizzy or fainting: in the blood draw, due to emotional overstress, fear, reflex caused by vagus nerve excitement, blood pressure decreased, etc. caused by insufficient blood supply to the brain caused by fainting or dizziness. 4. Risk of infection: If you use an unclean needle, you may be at risk of infection.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.